Synthetic oligonucleotides as therapeutic agents
1991
Synthetic Oligonucleotides as Cancer Treatments
Editorial
Evidence: low
Author Information
Author(s): D.M. Tidd
Primary Institution: Cancer Research Campaign Oncology Research Unit, The University of Liverpool
Hypothesis
Can synthetic oligonucleotides effectively inhibit gene expression in cancer and viral infections?
Conclusion
Synthetic oligonucleotides show promise as therapeutic agents, but their practical application is hindered by several limitations.
Supporting Evidence
- Antisense oligonucleotides can inhibit gene expression in cell-free systems.
- Short synthetic antisense oligonucleotides can be produced in larger amounts and are more sensitive to mismatches.
- Current oligonucleotide analogues have not yet proven to be universally effective against various cell types.
Takeaway
Scientists are excited about using tiny pieces of DNA to fight cancer and viruses, but there are still many challenges to overcome before they can be used safely in patients.
Limitations
Current antisense oligonucleotide technology faces issues like poor cell uptake, biological instability, and potential toxicity.
Want to read the original?
Access the complete publication on the publisher's website